Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study

Affiliations

• ¹ Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ² Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ³ Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁴ Roche/Genentech, South San Francisco, CA, USA.
• ⁵ Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁶ Department of Pathology, Yale-New Haven Hospital, New Haven, CT, USA.
• ⁷ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁸ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁹ Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹⁰ Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ¹¹ Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: dmhalperin@mdanderson.org.
• ¹² Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: rferrarotto@mdanderson.org.